Commentary: Public outreach by the FDA: evaluating oversight of human drugs and medical devices.
As nanotechnology emerges as an important public policy issue, the FDA's relationship with society is about to be tested. Most would agree that fostering public input will be critical to developing effective public policy for nanotechnology. Yet, it will not be easy. Low public confidence in the FDA, the general lack of knowledge about nanotechnology among ordinary Americans, and the way in which the "average" citizen obtains and evaluates knowledge about a public policy issue all pose serious challenges to any public outreach by the FDA. It will be necessary for the FDA to be attentive to not only its own public messages, but also to who is listening and how those messages are being perceived.
Frankel
Mark S
MS
Scientific Freedom, Responsibility and Law Program at American Association for Advancement of Science in Washington, DC, USA.
D003257:Consumer Product Safety; D004335:Drug and Narcotic Control; D006801:Humans; D050997:Nanomedicine / Q000331:legislation & jurisprudence*; D011050:Policy Making; D011639:Public Opinion; D014481:United States; D014486:United States Food and Drug Administration